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Abstract
Introduction—Current U.S. cervical cancer screening guidelines recommend a 3- or 5-year 
screening interval depending on age and screening modality. However, many women continue to 
be screened annually. The purpose of this study is to investigate U.S. women’s self-reported 
frequency of cervical cancer screening, acceptance of an extended screening interval (once every 
3–5 years), and preferred screening options.
Methods—Data from a 2012 web-based survey of U.S. women aged ≥18 years who had not 
undergone a hysterectomy or been diagnosed with cervical cancer (N=1,380) were analyzed in 
2014. Logistic regression models of extended screening interval use, acceptance, and preference 
were developed.
Results—Annual Pap testing was the most widely used (48.5%), accepted (61.0%), and 
preferred (51.1%) screening option. More than one third of respondents (34.4%) indicated that an 
extended screening interval would be acceptable, but only 6.3% reported that they were currently 
screened on an extended interval. Women who preferred an extended screening interval (32.9% of 
those willing to accept regular screening) were more likely to report no primary care visits during 
the last 12 months (AOR=2.05, p<0.003), no history of abnormal Pap test results (AOR=1.71, 
p=0.013), and that their last Pap test was performed by an internist/family practitioner rather than 
an obstetrician– gynecologist (AOR=2.03, p<0.001).
Conclusions—U.S. women’s acceptance of and preference for an extended cervical cancer 
screening interval appears to be more widespread than utilization. Strategies to educate women 
about the reasoning behind recommendations for less-than-annual testing and to foster informed 
preferences should be devised and evaluated.
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Many U.S. women continue to be screened annually for cervical cancer,1,2 even though less-
frequent testing has been endorsed by the American Cancer Society,3 American College of 
Obstetricians and Gynecologists,4 and U.S. Preventive Services Task Force (USPSTF)5 for 
more than a decade. Current guidelines issued by these organizations in 20126–8 recommend 
two major screening strategies: for women aged 21–29 years, Pap testing alone every 3 
years; for women aged 30–65 years, either Pap testing alone every 3 years or Pap testing 
with human papillomavirus (HPV) testing every 5 years. The recommended 3- and 5-year 
screening intervals reflect the limited benefit and potential harms associated with more 
frequent screening.8 The previous iteration of guidelines released in 2002–2003 varied by 
organization3–5; recommended screening intervals included annual, every 2 years, and every 
3 years, depending on age, screening history, and administration of the Pap test alone or in 
conjunction with the HPV test.
Although the cervical cancer screening preferences of providers have been the subject of a 
great deal of investigation,9–16 fewer studies have explored women’s acceptance of 
extended screening intervals. The small pool of studies investigating this topic found that 
37%–69% of women were resistant to following a 3-year screening interval.16–19 The 
present study investigated U.S. women’s self-reported frequency of cervical cancer 
screening, acceptance of an extended screening interval (a Pap test once every 3 years or a 
Pap test with an HPV test once every 3–5 years), and preferred screening option. 
Understanding women’s attitudes about extended screening intervals can inform strategies 
to increase adoption of screening recommendations.
Methods
The HealthStyles Fall survey is an annual survey conducted by Porter Novelli (Washington, 
DC) that explores the health behaviors and attitudes of U.S. adults. The 2012 HealthStyles 
Fall survey was administered online from September 21 to October 5. The survey items 
analyzed in the present study were licensed by CDC’s Inside Knowledge: Get the Facts 
About Gynecologic Cancer campaign (www.cdc.gov/cancer/knowledge), in order to inform 
the campaign’s efforts and development as well as other initiatives to increase women’s 
understanding of gynecologic cancer.
Study Sample
Participants in the 2012 HealthStyles Fall survey were recruited from the 
KnowledgePanel®,20 a 50,000-member online research panel that is randomly assembled 
and representative of the U.S. population. Panel members were recruited by probability-
based sampling (using both random-digit dial and address-based sampling methods) to reach 
potential respondents regardless of whether they had landline phones or Internet access. If 
needed, panel members were provided with a laptop computer and Internet access so they 
could take part in surveys.
The 2012 HealthStyles Fall survey was sent to a random sample of 4,371 panel members 
aged ≥18 years who responded to an earlier linked survey (HealthStyles Spring survey). A 
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total of 3,503 participants (1,733 men and 1,770 women) took part in the survey, for a 
completion rate of 80.1%. Women diagnosed with cervical cancer (n=24), and those who 
had had a hysterectomy (n=366) were excluded from analyses, resulting in a sample size of 
1,380. Women aged >65 years were included in the present study because many continue to 
participate in cervical cancer screening,21 despite the recommendation that screening should 
generally cease after age 65 years.6–8
To protect participant confidentiality, no individual identifiers were included in the data set 
received by investigators. As a result, analyses of data from the 2012 HealthStyles Fall 
survey were declared exempt by CDC’s IRB.
Measures
The analyzed items were developed by a multidisciplinary team, which included physicians, 
epidemiologists, social scientists, and methodologists, based on items previously 
administered in Health-Styles Fall surveys and other national surveys.
Current frequency of Pap test screening was assessed by asking: Typically, how often do you 
get a Pap test? Nine response options were provided: more often than once a year, once 
every year, once every 2 years, once every 3 years, once every 4 years, once every 5 years, 
once every 6 years or longer, I do not have regular Pap tests, and not sure. Only one 
response to this item was accepted. Current use of HPV testing was not assessed, as the 
USPSTF did not recommend HPV testing in conjunction with the Pap test as a cervical 
cancer screening modality until shortly before this study was conducted.8
Respondent’s acceptance of various screening options was assessed by asking: Which of the 
following cervical cancer screening options would be acceptable to you if your doctor 
recommended it for you? Seven response options were provided: Pap test once a year, Pap 
test once every 2 years, Pap test once every 3 years, Pap test with human papillomavirus 
(HPV) test once every 3 years, Pap test with HPV test once every 4 years, Pap test with HPV 
test once every 5 years, and none of these. Multiple responses were accepted unless none of 
these was selected. Although a Pap test administered in conjunction with an HPV test every 
3 years is not endorsed in current guidelines,6–8 this option was included in the response set, 
as it was previously reccommended3,4 and may have still been in use at the time of the 
study.
Respondents who indicated that they would accept a Pap test once every 1–3 years or a Pap 
test administered in conjunction with an HPV test once every 3–5 years were asked: If your 
doctor offered each of these cervical cancer screening options to you, which one would you 
prefer? Provided response options were the same as those in the previous item. Only one 
response to this item was accepted.
Women’s perception of the purpose of the Pap test was assessed by asking: To the best of 
your knowledge, the reason to have a Pap test or Pap smear is to check for which of the 
following? Seventeen possible responses were provided: anal cancer, bladder cancer, 
cervical cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, human 
papillomavirus (HPV) infection, pregnancy, ovarian cancer, ovarian cysts, sexually 
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transmitted diseases/infections (other than HPV), uterine cancer, uterine fibroids, vaginal 
cancer, vulvar cancer, none of these, and not sure. Multiple responses were accepted unless 
none of these or not sure was selected. Responses were classified into three categories: (1) 
selection of “cervical cancer” and no other responses; (2) other response combinations; and 
(3) not sure.
Statistical Analysis
The analyses reported here were conducted in 2014. Unweighted and weighted proportions 
(matched to 2012 U.S. estimates on age, household income, race/ethnicity, educational 
attainment, and geographic region) were calculted for participant characteristics, current 
frequency of Pap test screening, acceptable cervical cancer screening strategies, and 
preferred cervical cancer screening option. Additional descriptive analyses were conducted 
to assess the concordance and discordance between screening interval preferences and the 
Pap testing interval currently used.
Bivariate analyses were performed using Pearson chi-square tests to identify covariates 
associated with: (1) current use of 3-year screening interval (analyses were limited to 
women who reported receiving a Pap test once every 1–3 years); (2) acceptance of an 
extended screening interval (defined as a Pap test once every 3 years or a Pap test 
administered in conjunction with an HPV test once every 3–5 years); and (3) preference for 
an extended screening interval. All of the participant characteristics listed in Table 1 were 
tested as potential covariates, with one exception: the association between prior Pap test 
usage and having a Pap test once every 3 years was not tested, as evaluating use of an 
extended screening interval among women who had never been screened was not logical. 
All variables were categorized as shown in Table 1, with the exception of age, which was 
condensed into three groups (<30 years, 30–65 years, and >65 years) to provide age groups 
consistent with current screening recommendations.6–8
The covariates found to be significant (p<0.05) in the bivariate analyses were included in 
adjusted, forward-stepwise logistic regression models to predict the three outcome variables 
delineated above.
Results
The demographic distribution of the unweighted sample differed slightly from that of the 
weighted sample (Table 1). The largest discrepancy was found in race/ethnicity, with the 
sample including more participants who identified themselves as white, non-Hispanic than 
found in the U.S. adult population.
Overall, 19.7% of participants indicated that they did not have regular Pap tests, and 
significant differences were found by age that were consistent with current guidelines6–8: 
18–20 years (younger than recommended), 51.6%; 21–65 years (recommended age range), 
15.3%; >65 years (older than recommended), 27.2% (χ2=96.647, df=16, p<0.001, results not 
shown). Most women who reported not having regular Pap tests had health insurance 
(70.1%, results not shown).
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An annual Pap test was the most widely used (48.5%), accepted (61.0%), and preferred 
(51.1%) screening option. A minority of women (6.3%) reported that they currently received 
a Pap test once every 3 years (Figure 1). However, more than one third (34.4%) indicated 
that an extended screening interval would be acceptable to them if it was recommended by 
their doctor. In addition, 32.9% of those willing to accept regular screening (a Pap test every 
1–5 years) reported that they preferred an extended screening interval.
Among regularly screened women who reported a preference for an extended screening 
interval, less than one quarter (23.8%) reported that they received a Pap test once every 3 
years (Figure 2). Conversely, 89.2% of regularly screened women who reported a preference 
for annual screening were screened annually.
Covariates significantly associated with the target outcome variables in the bivariate 
analyses (results are included in the Appendix Table, available online) were included in the 
respective adjusted logistic regression models. Use of a 3-year Pap testing interval was less 
likely among women who reported three or more primary care visits during the last 12 
months and those who were uncertain about the purpose of the Pap test, and was more likely 
among women living in western U.S. states (Table 2). Acceptance of an extended screening 
interval was more likely among women who had received the HPV vaccine and those who 
had a prior Pap test. Acceptance was less likely among women who were uncertain about 
the purpose of the Pap test, black women, non-Hispanic women, and women who had 
completed high school or some college. Women who preferred an extended screening 
interval were more likely to report no primary care visits during the last 12 months, no 
history of abnormal Pap test results, and that their last Pap test was performed by an 
internist/family practioners.
Discussion
Acceptance of and preference for an extended screening interval was more widespread than 
utilization. More than one third of respondents indicated that an extended screening interval 
would be acceptable to them, but only 6.3% reported that they were currently screened on an 
extended interval.
The percentage of women in this study who did not find an extended screening interval 
acceptable (66%) is consistent with a 2002 survey of U.S. women aged ≥18 years (69%)17 
but higher than the rate found in a 2005 survey with U.S. women aged ≥40 years (37%).16 
Neither of these earlier surveys explored women’s preferences for an extended screening 
interval. In the present study, women who preferred an extended screening interval were 
more likely to report no primary care visits during the last 12 months, no history of 
abnormal Pap test results, and that their last Pap test was performed by an internist/family 
practitioner. A desire to minimize healthcare visits for convenience or other reasons may be 
the underlying characteristic that accounts for the associations with no primary care visits 
during the prior year and receipt of last Pap test from an internist/family practitioner, which 
may have been administered in the context of a one-stop, comprehensive health maintenance 
examination. Women with no prior history of abnormal Pap tests may be more comfortable 
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with an extended screening interval because they perceive that they have a low risk of 
developing gynecologic cancer.
Acceptance of an extended screening interval was higher among women in the present study 
who had received the HPV vaccine, which may be due to the perception that the vaccine 
affords a protective benefit. Also, women who were uncertain about the purpose of the Pap 
test were less likely to accept an extended screening interval than those with actual or 
perceived knowledge of the Pap test’s purpose. It is possible that women who believed that 
they lacked basic screening knowledge felt ill equipped to assess the implications of 
changing their current screening regimen. Other significant predictors associated with an 
increased likelihood of accepting an extended screening interval included race (white, non-
Hispanic), prior Pap test receipt, and educational attainment (graduate degree). The variables 
in the present study associated with acceptance of an extended screening interval differ from 
those previously identified. Acceptance of an extended screening interval was found to be 
higher among older women16,17 and lower among women with personal or family 
experience with cancer,16 those who knew someone diagnosed with cervical cancer,17 those 
who believed that screening guidelines were based on cost considerations,17 and those who 
were screened annually.16 Thus, no consistent markers for women’s willingness to adopt an 
extended screening interval have emerged.
Primary care visit volume was a key marker for current use of an extended screening 
interval, with women who reported no primary care visits (including gynecologist visits) 
during the last year being 12 times more likely to report current use of a 3-year screening 
interval than those with three or more visits. Dissecting which came first—less-frequent care 
seeking or an extended cervical cancer screening interval—is not possible. Clearly, some 
women may have been screened on a 3-year interval by default; however, others who 
purposefully follow an extended screening interval may have no perceived need to seek care 
during a given year.
It should be noted that two extended-interval screening options included in the present study 
are not currently recommended: Pap test with HPV test once every 3 years and Pap test with 
HPV test once every 4 years. During the period in which this study was conducted 
(September–October 2012), cervical cancer screening in the U.S. was in a period of 
transition, as current guidelines6–8 had only been released recently. Prior studies indicate 
that the incidence and timing of guideline adoption is variable.22–26 Thus, it is not surprising 
that an out-of-date screening recommendation—the Pap test with HPV test once every 3 
years3,4—was associated with higher levels of acceptance and preference than currently 
endorsed screening alternatives. It is also important to note that the present study 
investigated acceptable and preferred screening options in a hypothetical context, and 
women may respond differently in real life.
Limitations
The KnowledgePanel® from which study participants were recruited is a representative, 
random sample of U.S. households, which was created to meet the highest statistical 
standards for peer-reviewed research.20 Further, Internet research panels have been found to 
generate results that are comparable with other survey modes.27–29 The present study is 
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subject to the limitations of any analysis of self-reported survey data from participants in a 
preassembled research panel. Although data were weighted to reflect the U.S. population, 
the extent to which results are generalizable is not known. A high completion rate (80.1%) 
was achieved, which could be interpreted as strengthening the generalizability of results, but 
at the same time it raises questions as to whether respondents were more receptive to 
participating in research or more interested in health issues than the general population. As 
with all self-reported data, responses may have been influenced by social desirability bias, 
the tendency to answer questions in a manner that will be viewed favorably by others.30 
Also, black and Hispanic women, who are at highest risk of cervical cancer,31 were 
underrepresented in the sample, and the present study did not investigate whether women 
with prior abnormal Pap test results were candidates for more frequent screening. Future 
studies should attempt to oversample racial minorities and include a detailed assessment of 
cervical cancer screening history and follow-up treatment.
Conclusions
The current screening preferences of U.S. women may reflect long-held beliefs about the 
importance of annual Pap testing coupled with limited awareness of the potential harms 
associated with this practice. Women’s attitudes and beliefs related to screening frequency 
may differ if they reflected truly informed preferences32 and may be associated with less 
testing.33 From a provider perspective, annual cervical cancer screening has facilitated 
regular contact with patients. Thus, there are financial incentives for providers to screen 
annually, particularly for obstetrician– gynecologists who otherwise may not see patients for 
extended periods. Strategies may be needed to encourage providers to adopt recommended 
screening intervals and to educate women about the reasoning behind less-than-annual 
testing, including explicit discussions about the potential harms associated with 
overscreening.
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Extended cervical cancer screening interval use, acceptance, and preference.
Note: Data were from the 2012 HealthStyles Fall Survey of U.S. adults. The analysis 
presented in the figure was limited to women who had never been diagnosed with cervical 
cancer and had not undergone a hysterectomy (N=1,380), and data were weighted to match 
2012 U.S. Census estimates for age, household income, race/ethnicity, educational 
attainment, and geographic region.
*Only women who indicated that receiving a Pap test once every 1–5 years would be 
acceptable were asked to report a preferred cervical cancer screening option (n=1,134).
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Concordance and discordance between cervical cancer screening interval preference and 
use.
Note: Data were from the 2012 HealthStyles Fall Survey of U.S. adults. The analysis 
presented in the figure was limited to women who had the Pap test once every 3 years or 
more frequently, ≥1 prior Pap test, not undergone a hysterectomy, and never been diagnosed 
with cervical cancer, and data were weighted to match 2012 U.S. Census estimates for age, 
household income, race/ethnicity, educational attainment, and geographic region.
*Included Pap test more often than once a year, once every year, and once every 2 years.
†Included Pap test once every 2 years and once every 3 years.
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n (%) n (%)
Participant characteristics
  Age (years) 18–24 167 (12.1) 202 (14.2)
25–34 218 (15.8) 286 (20.0)
35–44 243 (17.6) 288 (20.2)
45–54 278 (20.1) 270 (18.9)
55–64 247 (17.9) 197 (13.8)
≥65 227 (16.4) 184 (12.9)
  Race/ethnicity White, non-Hispanic 1,022 (74.1) 927 (64.9)
Black, non-Hispanic 130 (9.4) 165 (11.6)
Other, non-Hispanic 76 (5.5) 99 (6.9)
Hispanic 152 (11.0) 237 (16.6)
  Educational attainment <High school 61 (4.4) 136 (9.5)
High school 369 (26.7) 452 (31.7)
Some college 445 (32.2) 422 (29.6)
Bachelor degree 336 (24.3) 299 (20.9)
Graduate degree 169 (12.2) 119 (8.3)
  Geographic region Northeast 282 (20.4) 286 (20.0)
Midwest 336 (24.3) 312 (21.9)
South 450 (32.6) 494 (34.6)
West 312 (22.6) 335 (23.5)
  Menopause status Post-menopausal 501 (36.6) 410 (28.9)
Peri-menopausal 123 (9.0) 118 (8.3)
Not post-or peri-menopausal 743 (54.4) 815 (62.7)
  Health insurance coverage Insured 1,133 (84.3) 1,117 (81.6)


















n (%) n (%)
Uninsured 211 (15.7) 252 (18.4)
  Number of primary care visits during the last 12 monthsc No visits 241 (17.6) 276 (19.6)
1–2 visits 711 (52.0) 740 (52.5)
≥3 visits 416 (30.4) 394 (27.9)
  Type of provider who performed most recent Pap test Obstetrician–gynecologist 635 (58.9) 608 (59.4)
Internist/family practitioner 298 (27.6) 274 (26.8)
Nurse practitioner/physician assistant 146 (13.5) 142 (13.9)
  Pap test usage ≥1 Pap test 1,104 (80.3) 1,054 (74.3)
No prior Pap test 270 (19.7) 365 (25.7)
  Lifetime abnormal Pap test result history ≥1 abnormal Pap result 187 (13.7) 176 (12.4)
No prior abnormal Pap result 1,182 (86.3) 1,242 (87.6)
  HPV test usage Had HPV test 126 (9.2) 121 (8.5)
No prior HPV test 1,24 (90.8) 1,299 (91.5)
  HPV vaccine reception Vaccinated 87 (6.3) 106 (7.5)
Unvaccinated 1,287 (93.7) 1,313 (92.5)
  Perceived purpose of Pap test Detection of cervical cancer exclusively 400 (29.3) 354 (25.2)
Other responses 783 (57.4) 821 (58.5)
Not sure 182 (13.3) 228 (16.3)
Current Pap testing interval
  More often than once a year 13 (1.0) 14 (1.0)
  Once every year 676 (49.5) 683 (48.5)
  Once every 2 years 230 (16.8) 218 (15.5)
  Once every 3 years 88 (6.4) 89 (6.3)
  Once every 4 years 10 (0.7) 10 (0.7)
  Once every 5 years 12 (0.9) 9 (0.6)
  Once every 6 years or longer 13 (1.0) 15 (1.1)
  I do not have regular Pap tests 255 (18.7) 277 (19.7)


















n (%) n (%)
  Not sure 68 (5.0) 94 (6.7)
Acceptable cervical cancer screening optionsd
  Pap test once a year 834 (62.0) 836 (61.0)
  Pap test once every 2 years 322 (23.9) 294 (21.5)
  Pap test once every 3 years 213 (15.8) 203 (14.8)
  Pap test with HPV test once every 3 years 314 (23.3) 314 (22.9)
  Pap test with HPV test once every 4 years 116 (8.6) 117 (8.5)
  Pap test with HPV test once every 5 years 123 (9.1) 132 (9.6)
  None of these 134 (10.0) 162 (11.9)
  Acceptance of 3-to 5-year screening intervale 468 (34.8) 471 (34.4)
Preferred cervical cancer screening optionf
  Pap test once a year 562 (49.6) 578 (51.1)
  Pap test once every 2 years 196 (17.3) 166 (14.6)
  Pap test once every 3 years 119 (10.5) 108 (9.5)
  Pap test with HPV test once every 3 years 147 (13.0) 151 (13.4)
  Pap test with HPV test once every 4 years 16 (1.4) 18 (1.6)
  Pap test with HPV test once every 5 years 76 (6.7) 95 (8.4)
  None of these 18 (1.6) 16 (1.4)
  Preference for 3-to 5-year screening intervale 358 (31.6) 371 (32.9)
Note: Data were from the 2012 HealthStyles Fall Survey of U.S. adults. The analysis presented in the table was limited to women who had never 
been diagnosed with cervical cancer and had not undergone a hysterectomy.
a
When variable responses do not sum to N, responses are missing unless otherwise noted.
b
Data were weighted to match 2012 U.S. Census estimates for age, household income, race/ethnicity, educational attainment, and geographic 
region.
c
Included visits to obstetrician–gynecologists, internists, and family practitioners.
d
Multiple responses to this item were accepted unless “none of these” was selected.
e
Included Pap test once every 3 years and a Pap test administered in conjunction with an HPV test once every 3–5 years.
f
Only respondents who indicated that receiving a Pap test every 1–5 years would be acceptable (n = 1,134) responded to this item.
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HPV, human papillomavirus.
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